NEW YORK, March 13 /PRNewswire/ -- On March 8, Dr. Mechael Kanovsky, Chief Executive Officer for Amazon Biotech, Inc. updated the investment community in an exclusive interview with www.wallst.net. Topics covered in the interview include an overview of the Company and the markets it serves, upcoming clinical trials, recent press releases, current capitalization, upcoming strategic and financial milestones.
To hear the interview in its entirety, visit http://www.wallst.net , and click on “Interviews.” The interview can be accessed either by locating the company’s ticker symbol under the appropriate exchange on the left-hand column of the “Interviews” section of the site, or by entering the company’s ticker symbol in the Search Archive window.
About Amazon Biotech, Inc.:
Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs.
AMZ0026 is the company’s first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or follow the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com .
To be included on the corporate e-mail list, send a request to LCGroup@mindspring.com.
Forward-Looking Statements
“Safe-Harbor” Statement Under the Private Securities Litigation Reform Act of 1995 -- This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words “believes,” “expects,” “anticipates,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech’s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof.
About WallSt.net:
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies. We are expecting to receive three thousand two hundred fifty dollars from Amazon Biotech, Inc. for media and advertising services. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp .
(Logo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGO)
Photo: http://www.newscom.com/cgi-bin/prnh/20050927/LATU121LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comWallStreet Direct, Inc.
CONTACT: Rick Lutz of LC Group, +1-404-261-1196, LCGroup@mindspring.com,for Amazon Biotech, Inc.; or Nick Iyer of Digital Wall Street, Inc.,1-800-4-WALL-ST
